Fig. 2: FBX8 promotes domancy of CRC in vitro.
From: FBX8 promotes metastatic dormancy of colorectal cancer in liver
a Western blot analysis was performed for CD44, SOX-2, CD133, and FBX8 in HT29 cells with 5 μmol/L concentrations of oxaliplatin and 5-FU combined chemotherapy, normalized to tubulin. b, c Effects of FBX8 on HT29 cells proliferation at 5 weeks by cell cycle assay. Data represent mean ± SD. d Effects of FBX8 on cell proliferation by CCK8 assay. Data represent mean ± SD. e Western blot analysis was performed for HIF-1α, C-Myc, CDK4, CD44, SOX-2, CD133, and FBX8 in HT29 cells with 5 μmol/L concentrations of oxaliplatin and 5-FU combined chemotherapy, normalized to tubulin. f Edu analysis was performed for the proliferation of HT29 cells with 5 μmol/L concentrations of oxaliplatin and 5-FU combined chemotherapy in vitro. Data represent mean ± SD. g Effects of FBX8 on HT29 cells proliferation at 5 weeks by CCK8 assay. Data represent mean ± SD. h Effects of FBX8 on HT29 cells proliferation at 5 weeks by cell cycle assay. Data represent mean ± SD. i Western blot analysis was performed for HIF-1α, C-Myc, CDK4, CD44, SOX-2, CD133, and FBX8 in HT29 cells with 5 μmol/L concentrations of oxaliplatin and 5-FU combined chemotherapy, normalized to tubulin. *P < 0.05, **P < 0.01, ***P < 0.001.
